H
Haemonetics Corporation
HAE · Healthcare
Q3 FY2026
Earning ended Dec 27, 2025Report generated Mar 10, 2026
TEG's Clinical Protocol Lock-In Is Priced Like Commodity Hardware
The market re-rated Haemonetics from high-growth medtech to mature healthcare supplier and compressed the multiple by three-quarters over four years — but TEG is not commodity hardware; it is a clinical decision node embedded in cardiac surgery and trauma protocols with decades of peer-reviewed outcomes data anchoring it in place, and that institutional stickiness compounds quietly in ways the income statement chronically understates.
Flowly Score
Apr 16 Close
+208%$60.11
Fair Value
$185.00
66
Strongat $60.11
Business Strength7/10
The razor-and-blades model is genuinely sticky — TEG results embedded in surgical protocols make ripping out the device feel like institutional self-harm — but Plasma's revenue concentration in a handful of massive collectors creates customer leverage that structurally caps pricing power in ways that aren't visible until a contract renewal arrives.
Financial Resilience6/10
Cash conversion quality is excellent — FCF has exceeded net income consistently and operating cash flow more than doubled year-over-year in the latest quarter — but the Altman Z sitting in the grey zone and $1.2B in total debt against a $3B market cap means this balance sheet demands respect, not comfort, particularly with convertible notes coming due.
Growth & Trajectory7/10
The reported revenue decline masks a genuinely healthy organic story — plasma growing organically at 20%+ and Hospital TEG disposables accelerating — while operating leverage is converting modest top-line momentum into double-digit earnings expansion; the IVT segment remains the open wound that keeps this from being a cleaner, higher-conviction trajectory.
Valuation7/10at $64.23
A compression from 70x to 19x has repriced this as commodity medtech when the underlying platform is anything but; FCF yield and EV/EBITDA both suggest the market is embedding pessimism that the organic business fundamentals — 60%+ gross margins, tripling free cash flow, raised guidance — simply do not support.
Risk5/10
Three concrete threats deserve naming: Werfen's ClotPro is a genuine clinical competitor eroding TEG's evidence-moat advantage in European surgical centers; plasma customer concentration means one aggressive contract renegotiation can visibly impair segment economics in a single quarter; and the Cardiva/IVT chapter remains an unresolved capital allocation question mark that clouds the management trust calculus.
The investment case is a quality cash-generating business catching a meaningful valuation break. Operating margins are expanding toward 26%, gross margins have crossed 60% as high-frequency consumables dominate the mix, and free cash flow conversion is running well above reported earnings — yet the stock is priced as though this earning power is temporary and fragile. That valuation gap only makes sense if you believe the current trajectory is unsustainable, and the segment data doesn't support that conclusion. The multiple compression tells a story of narrative collapse; the fundamentals tell a different story. The business is heading toward a two-engine structure: Hospital TEG as the compounding growth driver, Plasma as the disciplined cash cow. TEG adoption still has real runway — trauma bays, obstetric hemorrhage management, mid-sized surgical centers — and the compounding dynamic is underappreciated. Every new center that builds a TEG-anchored protocol deepens the published outcomes evidence, which accelerates the next center's adoption decision, which deepens the literature further. That is a network-effect-adjacent moat dressed up in the language of a hardware placement cycle, and the market is treating it like a one-time transaction. The IVT recovery is a wildcard, but it is not structurally broken — the vascular closure market is real, the salesforce immaturity is fixable, and the VIVUSHORE acquisition addresses the large-bore gap directly. The single biggest specific risk is plasma customer concentration. A small number of massive plasma collectors account for the preponderance of Plasma disposables revenue. These are sophisticated, well-capitalized counterparties who are fully aware of their leverage at contract renewal time, and there is no amount of product differentiation that fully neutralizes the structural negotiating disadvantage of a supplier whose product is mission-critical to a customer who knows it. One aggressive renegotiation cycle could compress segment margins visibly in a single quarter — and that kind of surprise is precisely what turns a 19x multiple into a 13x multiple before the earnings call ends.